Genetic Analysis (GEAN) Q2 2026 earnings summary

Executive summary

• Achieved recurring revenue growth in core reagent kit products, with global expansion and scientific validation supporting platform adoption.

• Launched Alnsight, an AI-assisted interpretation platform, and advanced the GA-map® IBD Precision Dx project toward a 2026 launch.

• Secured a new US patent and expanded laboratory installations to Australia, now covering four continents.

Financial highlights

• Q2 2026 sales revenue was NOK 5.3 million, down 10.2% year-over-year (4% decrease at constant currency).

• Gross margin reached 91.2% in Q2 2026, positively impacted by a one-time accrual for US customs duty refunds; adjusted gross margin was 72.5%.

• EBITDA for Q2 2026 was NOK -1.0 million, compared to NOK 0.5 million in Q2 2025.

• Net loss for Q2 2026 was NOK -2.4 million, compared to NOK -1.0 million in Q2 2025.

• Cash and cash equivalents at June 30, 2026, were NOK 14.5 million, down from NOK 24.0 million at year-end 2025.

Outlook and guidance

• Expects continued revenue growth driven by increased adoption of GA-map® solutions and expansion in Europe, US, and China.

• Anticipates new customer interest with the launch of GA-map® IBD Precision Dx in H2 2026.

• Growth to be supported by scaling reagent kit sales, demand for standardized microbiome testing, and new product rollouts.